Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 17, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,300,000 ordinary shares of 25 pence each.
- Purchase Price: 1,075.04 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 8.98% of total voting rights).
- Shares in Issue: 5,390,098,040 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,300,000 shares purchased on April 17, 2008. Consequently, the number of shares held in Treasury has been updated to reflect this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the buyback by multiplying 2,300,000 shares by the price of 1,075.04 pence.
- Confirm the updated Treasury share count of 484,194,158 and its impact on the 8.98% voting rights representation.
- Note that the denominator for shareholder notification thresholds under Disclosure and Transparency Rules is now 5,390,098,040 shares.
- Recognize that this filing is a regulatory disclosure of a capital transaction and does not contain operational or financial performance data.